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Use of data from registered clinical trials to identify gaps in health 
research and development
Roderik F Viergever,a Robert F Terryb & Ghassan Karamc
Introduction
More than two decades ago it was shown that only 5% of 
the world’s resources for health research and development 
(R&D) were spent on the health problems of developing 
countries, which then represented 93% of the world’s burden 
of preventable mortality.1,2 The lack of a rational link between 
the health R&D that was needed and that which was being 
conducted resulted in the existence of “neglected popula-
tions”.3 This mismatch, which still exists, had and has two main 
causes. First, the distribution of R&D funding has been – and 
remains – largely determined by market forces rather than 
by a more equitable system that is based on health needs.4,5 
Second, even when funding for health R&D is distributed by 
philanthropic or governmental donors, many high-burden 
diseases and priority areas of R&D can remain badly under-
funded.6 This indicates a lack of appropriate mechanisms 
for the prioritization and coordination of such R&D.7 To 
start addressing these problems, a sense of agreement on a 
common R&D agenda will have to grow among funders of 
health R&D – something that, to date, has proven difficult to 
achieve.7 As a first step towards such a common agenda, the 
current composition of the “global landscape” of health R&D 
needs to be explored so that the gaps in this landscape and 
neglected populations can be identified. If we are to change 
how we spend our money on health R&D, we first need to 
know how we are spending it now.
Unfortunately, we know very little about what health R&D 
is being conducted, where and how it is being conducted, 
and who is conducting it.8 Databases of registered clinical 
trials may offer a new resource for gaining insight into the 
health R&D “landscape”. In the past decade, trial registra-
tion has become broadly accepted as an ethical and scientific 
responsibility.9–16 Enforcing regulations, policies and legisla-
tion has been crucial to the success of trial registration. There 
has been relevant national legislation,12 the editors of many 
medical journals have made trial registration a prerequisite 
for the publication of trial results,9,13–15 such registration may 
also now be a prerequisite for the ethical approval of a trial’s 
protocol11,17 and a self-regulating pharmaceutical industry has 
also promoted trial registration.16 On several continents, many 
publicly accessible, online registries have been established to 
allow investigators to register their clinical trials.18 In 2005, 
the International Clinical Trials Registry Platform (ICTRP) 
was established by the World Health Organization (WHO) to 
create a platform for linking these clinical trial registries and 
provide a single point of access to information on all clinical 
trials conducted globally.11 Over the last 8 years, the ICTRP 
has grown into a platform that combines data from 15 different 
clinical-trial registries, both national and regional, and offers 
access to more than 200 000 registered records of clinical trials.
This study was conducted to explore what can be learnt 
from the clinical trial records available on the ICTRP database 
about the current composition of the “global landscape” of 
health R&D. We were especially interested in the distribu-
tion of trials across different diseases and countries and the 
identification of any major gaps in the “landscape”.
Methods
Study sample
By using an automated random sampling function that is 
available as part of the ICTRP’s data management system, 
we randomly selected from the ICTRP database 5% of all the 
records for interventional clinical trials that were registered 
as actively recruiting participants on 10 August 2012. A 5% 
sample was considered to be sufficient to produce results that 
Objective To explore what can be learnt about the current composition of the “global landscape” of health research and development 
(R&D) from data on the World Health Organization’s International Clinical Trials Registry Platform (ICTRP).
Methods A random 5% sample of the records of clinical trials that were registered as interventional and actively recruiting was taken from 
the ICTRP database.
Findings Overall, 2381 records of trials were investigated. Analysis of these records indicated that, for every million disability-adjusted 
life years (DALYs) caused by communicable, maternal, perinatal and nutritional conditions, by noncommunicable diseases, or by injuries, 
the ICTRP database contained an estimated 7.4, 52.4 and 6.0 trials in which these causes of burden of disease were being investigated, 
respectively. For every million DALYs in high-income, upper-middle-income, lower-middle-income and low-income countries, an estimated 
292.7, 13.4, 3.0 and 0.8 registered trials, respectively, were recruiting in such countries.
Conclusion The ICTRP constitutes a valuable resource for assessing the global distribution of clinical trials and for informing policy 
development for health R&D. Populations in lower-income countries receive much less attention, in terms of clinical trial research, than 
populations in higher-income countries.
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could give a general view, but not too 
large to hamper the manual extraction 
of relevant data. For trials that were 
registered in more than one registry, we 
included only the record with the earli-
est registration date.19 We excluded trials 
that, according to the ICTRP’s records, 
were only observational in nature.
Data extraction
Registry name, date of registration, age 
and sex inclusion criteria, target sample 
size, study design, study type, study 
phase and the countries of recruitment 
for each record were downloaded from 
the ICTRP and imported into an Excel 
(Microsoft, Redmond, United States 
of America) database on 10 August 
2012. We manually reviewed the health 
condition or problem studied, the in-
tervention and the primary sponsor by 
examining the registered record, and we 
then coded the data as described in the 
next section.
Data coding and classifications
We coded the health conditions or 
problems studied in each selected trial 
according to table C3 of the Global bur-
den of disease: 2004 update.20
We categorized the countries in 
which the subjects of trials were re-
cruited as high-, upper-middle-, lower-
middle- or low-income according to 
the World Bank’s groupings, which are 
based on gross national incomes per 
capita.21 We also identified the WHO 
region to which each country belonged 
using the current WHO classification of 
Member States.22 If a trial was recruiting 
participants in multiple countries that 
belonged to the same income group 
or same WHO region, we counted the 
group or region only once.
We divided primary sponsors (i.e. 
the individual, organization, group 
or other legal entity that was respon-
sible for initiating, managing and/or 
financing a trial) into nine categories: 
collaborative groups of researchers or 
doctors; contract research organizations; 
foundations; government institutions; 
industries; individuals registered as 
sponsors; research institutes; universi-
ties or hospitals; and “other”. We then 
classified trials as having an industrial 
primary sponsor, a non-industrial pri-
mary sponsor (including collaborative 
groups, foundations, governments, 
research institutes and universities or 
hospitals) or another type of sponsor 
(including individuals registered as 
primary sponsors, contract research 
organizations and “other” sponsors).
All data were extracted and coded 
by one author (RFV) and, if ambiguous, 
discussed with another author (RFT).
Data analysis
For each health condition or problem 
studied and for each of the categories 
used for the countries of recruitment, 
the number of trials detected in the 5% 
sample was extrapolated to estimate 
the total number of actively recruit-
ing, interventional trials with the same 
characteristic that were registered on 
the ICTRP. The Wilson score interval23 
was used to calculate 95% confidence 
intervals for each estimate.
Whenever possible, for each health 
condition or problem studied, we 
mapped the estimated total number of 
related trials on the ICTRP against the 
corresponding burden of disease in dis-
ability-adjusted life years (DALYs).20,24 
Additionally, we divided the estimated 
total number of related trials by the cor-
responding burden of disease in DALYs 
to give an estimate of the total number of 
trials per million DALYs for each health 
condition. Burden-of-disease data 
were not available for all of the health 
conditions that were being investigated 
in the selected trials.24 In addition, the 
subcauses of injuries were ignored in 
these calculations because the sources 
of the injuries were not included in the 
majority of the records pertaining to 
injuries. Among the health conditions 
and problems, we also excluded residual 
(“other”) categories, several overarching 
categories (i.e. skin disorders, endocrine 
disorders and “other neoplasms”) and 
a small number of specific diseases for 
which uncertainties in the burden-of-
disease estimates were large (e.g. chla-
mydia, gonorrhoea, neonatal infections, 
polio, all congenital anomalies, all oral 
diseases and Chagas disease in low-
income countries). Trials that recruited 
participants with malignant neoplasms 
in general were redistributed propor-
tionally over all of the disease codes for 
such neoplasms, in a similar approach to 
that taken by the authors of the Global 
burden of disease: 2004 update.20
We expressed estimates of the 
numbers of trials in the ICTRP database 
that were recruiting in countries in each 
income group and WHO region as the 
numbers of trials per capita. For this, 
we estimated the sizes of the relevant 
national populations in the year 2012 us-
ing the World Bank’s database of health, 
nutrition and population statistics.25 For 
each income group and WHO region, we 
divided the number of trials per capita 
by the corresponding total burden of 
disease in DALYs per capita to obtain 
an estimate of the total number of trials 
per million DALYs for each category 
used for the countries of recruitment.
We derived all burden-of-disease 
data – which were standard DALYs with 
time discounting and age-weighting – 
from the most recently published results 
of WHO’s Global Burden of Disease 
study.20,24
We used Z-tests23 to compare the 
proportions of trials whose primary 
sponsor was industrial with the cor-
responding proportions of trials with 
non-industrial primary sponsors.
All of the data analysis was con-
ducted using the Excel software package.
Results
On 10 August 2012, 2381 clinical trials 
that were registered as interventional 
and actively recruiting were randomly 
selected from the ICTRP database 
(Fig. 1). Baseline information on reg-
istry name, intervention type, year of 
registration, sponsorship, target sample 
size, study phase and inclusion criteria 
for sex and age of participants is pre-
sented in Table 1.
Health conditions or problems 
studied
The health condition or problem stud-
ied could be classified for 2195 of the 
2381 selected trials. The most common 
focus of investigation – both in terms 
of the absolute number of trials and 
the number of trials per million DALYs 
caused by the condition or problem 
– was on noncommunicable diseases 
(52.4), followed first by communicable, 
maternal, perinatal and nutritional con-
ditions (7.4) and then by injuries (6.0) 
(Table 2, available at: http://www.who.
int/bulletin/volumes/91/6/12-114454, 
and Fig. 2). The estimated total number 
of trials registered on the ICTRP for 
each health condition or problem was 
mapped against the global burden of the 
condition or problem (Fig. 3).
Countries of recruitment and 
sponsorship
Information on countries of recruit-
ment was available for 2377 of the 
2381 selected trials. Trials were found 
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to recruit most often in high-income 
countries – absolutely, per capita and 
proportionally to the burden of disease 
in these countries – followed first by 
upper-middle-income countries, then 
by lower-middle-income countries and 
finally by low-income countries (Table 3 
and Fig. 4). Trials recruited most often 
were in WHO’s European Region and 
the Region of the Americas (Table 3 
and Fig. 5).
We were able to determine coun-
try of recruitment and classify the 
primary sponsor as non-industrial or 
industrial for 2253 of the 2381 selected 
trials. Trials with non-industrial pri-
mary sponsors recruited more often in 
low-income countries than trials with 
industrial primary sponsors (odds ra-
tio, OR: ∞; Z = 2.0; P = 0.0464), whereas 
trials with industrial primary sponsors 
recruited more often in lower-middle-
income (OR: 4.0; Z = 7.2; P < 0.0001), 
upper-middle-income (OR: 2.0; Z = 5.0; 
P < 0.0001) and high-income countries 
(OR: 2.2; Z = 4.0; P = 0.0001) (Table 4). 
Trials with industrial primary sponsors 
were more likely to have multi-country 
recruitment [222 (44.8%) of 495] than 
trials with non-industrial primary 
sponsors [73 (4.1%) of 1758] (OR: 18.8; 
Z = 23.7; P < 0.0001).
Discussion
The global monitoring of health R&D 
requires analyses of the inputs (e.g. in-
vestments),2,5,6 processes (e.g. analyses of 
the R&D “pipeline”)26,27 and outputs (e.g. 
publications28 or products such as medi-
cines)4 of R&D. Such “triangulation” of 
different sources of information is essen-
tial if we are to obtain a complete picture 
of what health R&D is being conducted, 
where and how it is being conducted, 
and who is conducting it. The increas-
ing public availability of information 
on clinical trials provides an additional 
source of information for analysing cur-
rent processes in health R&D at global, 
regional or country levels. Evaluations of 
registered trial data have recently been 
used to shed light on national clinical 
trial portfolios29,30 and specific research 
areas.31–34 This type of evaluation has 
several strengths: all trials should be 
registered, even if their final results are 
never published; registered records con-
tain information that is complementary 
to that in any published articles on the 
trials;35 databases of registered trials can 
provide insight into currently ongo-
ing R&D; and their standardized and 
searchable format makes databases of 
registered trials suitable for aggregate 
analysis.36 For the purpose of obtain-
ing a comprehensive global picture of 
all ongoing clinical trials, the ICTRP is 
an unmatched resource of information 
since it provides access to data from 
all of the major clinical trial registries 
around the world that meet the relevant 
standards of WHO’s registry criteria.37
The results of this study show 
that, at least on a global scale, there is 
little correlation between the burden 
of disease attributable to a particular 
health condition or problem and the 
amount of clinical trial research being 
conducted on that health problem. 
This finding confirms the mismatch 
– between health R&D need and rel-
evant health R&D – that has previously 
been observed using alternative R&D 
metrics, such as R&D investments and 
R&D outputs.1–4,6,33,38 A consequence 
of this mismatch is the existence of 
several populations that are neglected 
with respect to health R&D.3 In par-
ticular, health R&D currently does not 
adequately meet the needs of popula-
tions in lower-income countries.3,39 
In general, communicable, maternal, 
perinatal and nutritional conditions 
– which cause a much higher propor-
tion of the burden of disease in lower-
income countries than in high-income 
countries20 – currently receive much 
less attention, in terms of clinical trial 
research, than noncommunicable dis-
eases. In addition, clinical trials recruit 
much less often in lower-income coun-
tries than in higher-income countries. 
For health conditions or problems that 
cause a large burden in both lower- and 
higher-income countries, it is impor-
tant that populations in lower-income 
countries be included in clinical trial 
research so that their specific R&D 
needs can be addressed.3
There are several limitations in us-
ing registered trial data for identifying 
gaps in the health R&D “landscape”. 
No account is taken of research other 
than that conducted within the context 
of a clinical trial. Since a registry for 
systematic reviews has recently been 
established40 and the creation of a 
Fig. 1. Flowchart of the sampling of the records of interventional and actively recruiting 
trials in the International Clinical Trials Registry Platform (ICTRP), 2012
212 265 registered records of clinical trials 
in the ICTRP
74 240 records of actively 
recruiting trials
For 2195 trials: information on health 
problem studied
For 2377 trials: information on country or 
countries of recruitment
ICTRP search – 10 August 2012
Exclusion of non-recruiting trials
5% random sample
Removal of duplicates
Exclusion of observational trials
57 822 records of unique trials
2891 trials
2381 trials
Data extraction
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Category No. (%) of selected 
trials (n = 2381)
Registry name
CT.gov 1316 (55.3)
EU-CTR 540 (22.7)
JPRN 208 (8.7)
ANZCTR 95 (4.0)
ISRCTN 61 (2.6)
ChiCTR 43 (1.8)
CTRI 36 (1.5)
NTR 31 (1.3)
IRCT 23 (1.0)
DRKS 16 (0.7)
CRiS 9 (0.4)
ReBec 2 (0.1)
PACTR 1 (0.0)
RPCEC 0 (0)
SLCTR 0 (0)
Intervention typea
Drugs and biologicals 1562 (65.6)
Surgery and other proceduresb 281 (11.8)
Behaviouralc 168 (7.1)
Device 167 (7.0)
Diagnostic 119 (5.0)
Dietary supplements and diets 106 (4.5)
Physical therapy 64 (2.7)
Radiation 48 (2.0)
Organizational 42 (1.8)
Other 35 (1.5)
Year of registration
Before 2005 26 (1.1)
2005 127 (5.3)
2006 106 (4.5)
2007 158 (6.6)
2008 245 (10.3)
2009 351 (14.7)
2010 462 (19.4)
2011 544 (22.8)
2012 362 (15.2)
Category No. (%) of selected 
trials (n = 2381)
Primary sponsor
University or hospital 1459 (61.3)
Industry 495 (20.8)
Collaborative group of doctors or researchers 112 (4.7)
Government institution 99 (4.2)
Individual 97 (4.1)
Research institute 51 (2.1)
Foundation 40 (1.7)
Contract research organization 4 (0.2)
Other 2 (0.1)
Not specified or not classifiable 22 (0.9)
Target number of participants
1–99 1184 (49.7)
100–999 832 (34.9)
≥ 1000 94 (3.9)
Not specified 271 (11.4)
Study phase(s)
0 11 (0.5)
I 166 (7.0)
I/II 86 (3.6)
II 432 (18.1)
II/III 44 (1.8)
III 265 (11.1)
III/IV 1 (0.0)
IV 230 (9.7)
Not specified 1146 (48.2)
Sex of participants
Both 2028 (85.2)
Female 257 (10.8)
Male 96 (4.0)
Age of participantsa
0–27 days 76 (3.2)
28 days–2 years 111 (4.7)
2–11 years 200 (8.4)
< 12 years 247 (10.4)
12–17 years 280 (11.8)
< 18 years 372 (15.6)
18–64 years 2034 (85.4)
≥  65 years 1582 (66.4)
Not specified 127 (5.3)
Table 1. Baseline information on a 5% sample of trials from the International Clinical Trials Registry Platform, 2012
ANZCTR, Australian New Zealand Clinical Trials Registry; ChiCTR, Chinese Clinical Trial Register; CRiS, Clinical Research Information Service of the Republic of Korea; 
CT.gov, ClinicalTrials.gov; CTRI, Clinical Trials Registry – India; DRKS, German Clinical Trials Register; EU-CTR, EU Clinical Trials Register; IRCT, Iranian Registry of Clinical 
Trials; ISRCTN, International Standard Randomized Controlled Trial Number Register; JPRN, Japan Primary Registries Network; NTR, Netherlands National Trial Register; 
PACTR, Pan African Clinical Trial Registry; ReBec, Brazilian Clinical Trials Registry; RPCEC, Cuban Public Registry of Clinical Trials; SLCTR, Sri Lanka Clinical Trials Registry.
a  As some of the classifications within this category overlap, some trials are included in more than one classification.
b  “Other procedures” included acupuncture and cell transplants.
C  For example, psychotherapy and lifestyle counselling.
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registry for observational research has 
been widely advocated,41,42 evaluations 
of the health R&D “landscape” may 
soon broaden in scope. Another poten-
tial data source could be a registry (or 
database) of research protocols or even 
raw datasets43, although the information 
in such a registry would be much more 
difficult to analyse than the registered 
records of clinical trials.
The need for clinical trial research 
on a given health problem – or the 
perceived need for such research – is 
only partly determined by the burden 
of disease posed by the problem. The 
severity of the corresponding product 
shortfall, the state of the relevant sci-
ence and technology and disease trends 
can also affect the need for clinical trial 
research.6,44 In other words, the need for 
R&D will be relatively high for diseases 
for which effective product develop-
ment has been scant and for emerging 
diseases, diseases posing increasing 
burdens and diseases on course for 
eradication, whereas clinical trials may 
be considered premature if basic science 
is lacking in new research areas. Caution 
is therefore warranted in interpreting 
the correlation – or lack of correlation 
– between the number of clinical trials 
conducted on a particular disease and 
the burden posed by that disease. The 
main strength of the findings of the 
present study lies in the general, global 
trends that the findings reveal. For more 
specific conclusions about individual 
diseases, registered trial data will have 
to be analysed alongside other sources 
of information.
To date, very little reliable infor-
mation has been produced on how 
much clinical trial research is being 
conducted in lower-income countries.45 
Although the present results help to fill 
this knowledge gap, it is important to 
note that the registration of trials has 
not been enforced equally around the 
world. Many countries still have no 
legislation to enforce registration12 and 
not all journals in which clinical-trial 
data could be published are covered by 
the journal associations that have com-
mitted to enforcing trial registration.9,13 
Furthermore, not all clinical trials are 
conducted with the goal of publication. 
It is difficult to verify or even estimate 
how many clinical trials remain unreg-
istered, although it seems likely that at 
least some trials are never registered, 
especially in countries where there is no 
legal requirement for registration.30,46,47 
Given that all major medical journals 
now require evidence of trial registra-
tion, as a condition for publication of 
any data from a trial, and that all studies 
that assess the effects of new medicines 
– for which regulatory approval is to 
be sought internationally – need to be 
registered, the quality and potential 
impact of any unregistered trials are 
questionable. Nonetheless, it is crucial 
Fig. 2. Health problems being investigated by trials registered in the International 
Clinical Trials Registry Platform (ICTRP), 2012
Injuries
1120 (2.6%)
Injuries
188 million (12.3%)
Communicable,
maternal, perinatal 
and nutritional 
conditions
4440 (10.1%)
Communicable,
maternal, perinatal 
and nutritional conditions
604 million (39.7%)
Noncommunicable diseases
38 340 (87.3%)
Noncommunicable diseases
732 million (48.0%)
DALYsEstimated no. of trials
DALY, disability-adjusted life year.
Note: Only interventional and actively recruiting trials were investigated. The health problems are split 
according to both the estimated numbers of trials on the ICTRP (lefthand chart) and the burden of 
disease that they cause globally (righthand chart). Confidence intervals were calculated for the estimates 
but have been omitted from the figure, for clarity.
Fig. 3. Estimated number of trials in the International Clinical Trials Registry Platform 
investigating a specific health problem and the burden of disease posed by that 
problem, 2012
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Note: Only interventional and actively recruiting trials were included in the analysis. Data in the grey area 
are for health problems that have 400 or fewer registered trials and a global burden of disease of less 
than 20 million. A full list of registered trials by health problem is shown in Table 2 (available at: http://
www.who.int/bulletin/volumes/91/6/12-114454). Only trials investigating specific health problems were 
included in this figure; overarching categories and subcategories of health problems were excluded. 
Confidence intervals were calculated for the estimates but have been omitted from the figure, for clarity.
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that clinical-trial registration is enforced 
in every country, by means of national 
legislation and/or by ethical review 
boards, to ensure that a complete picture 
of the global distribution of clinical-trial 
research can be obtained.11,12,48
Before full use can be made of the 
ICTRP for exploring the health R&D 
“landscape”, several other limitations 
need to be addressed. First, even in those 
countries that have legislation on the 
registration of clinical trials, enforced 
registration is often limited to trials of 
drugs and – sometimes – devices, phase 
II–IV trials, and trials that recruit sub-
jects in the country where the legislation 
is implemented.49 This problem has been 
recognized in the United States of Amer-
ica, where new legislation to ensure that 
all clinical trials of interventions are 
registered has been proposed.50 There 
also remain concerns about the quality 
of the data entered into the registered 
records of clinical trials10,51,52 and about 
problems with the unique identification 
of trials, which can lead to duplicate 
registration.19
Finally, the extraction, aggregation 
and analysis of the data in the ICTRP 
database currently require substantial 
Table 3. Areas of recruitment for the actively recruiting, interventional trials registered in the International Clinical Trials Registry 
Platform (ICTRP), 2012
Area of recruitment No. of trials 
in samplea
Estimate
Percentage (95% CI) 
of trials in ICTRPb 
No. (95% CI) of trials in ICTRP 
Total Per 1 000 000  
inhabitants
Per 1 000 000  
DALYs
World Bank income group21
High-income country 2115 89.0 (87.7–90.2) 42 300 (41 671–42 869) 37.2 (36.7–37.7) 292.7 (288.4–296.7)
Upper-middle-income country 292 12.3 (11.0–13.7) 5840 (5241–6496) 2.4 (2.1–2.6) 13.4 (12.0–14.9)
Lower-middle-income country 111 4.7 (3.9–5.6) 2220 (1850–2659) 0.9 (0.7–1.0) 3.0 (2.5–3.6)
Low-income country 14 0.6 (0.4–1.0) 280 (167–469) 0.3 (0.2–0.6) 0.8 (0.5–1.3)
WHO region22
Africa 50 2.1 (1.6–2.8) 1000 (760–1313) 1.1 (0.9–1.5) 2.2 (1.7–2.9)
Americas 840 35.3 (33.4–37.3) 16 800 (15 898–17 724) 17.7 (16.7–18.7) 107.9 (102.1–113.8)
Eastern Mediterranean 65 2.7 (2.2–3.5) 1300 (1023–1650) 2.1 (1.6–2.6) 7.6 (6.0–9.7)
Europe 1055 44.4 (42.4–46.4) 21 100 (20 156-22 053) 23.4 (22.3–24.4) 136.3 (130.2–142.5)
South-East Asia 96 4.0 (3.3–4.9) 1920 (1578–2333) 1.0 (0.9–1.3) 3.9 (3.2–4.8)
Western Pacific 548 23.1 (21.4–24.8) 10 960 (10 176-11 785) 6.0 (5.6–6.5) 39.7 (36.8–42.6)
CI, confidence interval; DALY, disability-adjusted life year; WHO, World Health Organization.
a  Estimated percentages and numbers for the whole ICTRP were based on the results of the analysis of the records for a 5% sample of the trials registered on the 
platform.
b  The percentages shown are those of the 2377 trials in the sample for which the country or countries of recruitment could be determined from the registered records. 
When summed, the percentages shown for income groups or regions exceed 100% because some trials were recruiting in multiple countries belonging to more 
than one income group or region.
Fig. 4. Estimated numbers of trials in the International Clinical Trials Registry Platform 
recruiting participants in low-, lower-middle-, upper-middle- and high-income 
countries, 2012
Income group of country of recruitment
Estimated no. of trials Burden of disease
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DALY, disability-adjusted life year.
Note: Only interventional and actively recruiting trials were included in the analysis. For illustration, the 
burdens of disease in countries in the same income groups are also presented. The error bars on the 
estimates of trial numbers indicate 95% confidence intervals.
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صخلم
ةحصلا لامج في ريوطتلاو ثحبلا في تارغثلا ديدحتل ةلجسلما ةيريسرلا براجتلا نم تانايبلا مادختسا
 نأشب  اهنم  ةدافتسلاا  نكمي  يتلا  سوردلا  ضارعتسا  ضرغلا
 لامج  في  ريوطتلاو  ثحبلل  “يلماعلا  دهشملل”  نهارلا  نيوكتلا
 براجتلا  ليجستل  ليودلا  جمانبرلاب  ةينعلما  تانايبلا  نم  ةحصلا
.)ICTRP( ةيلماعلا ةحصلا ةمظنلم عباتلا ةيريسرلا
 براجتلا تلاجس نم % 5 اهتبسن ةيئاوشع ةنيع ذخأ مت ةقيرطلا
 لىع  ةيفيظوتو  ةيلخدت  اهرابتعاب  اهليجست  مت  يتلا  ةيريسرلا
 براجتلا  ليجستل  ليودلا  جمانبرلا  تانايب  ةدعاق  نم  طشن  وحن
.ةيريسرلا
 .براجتلا  نم  ًلاجس  2381  صحف  مت  ،لياجمإ  لكشب  جئاتنلا
 ةنس  نويلم  لكل  ةبسنلاب  هنأ  لىإ  تلاجسلا  هذه  ليلتح  راشأو
manual labour. The formats of some of 
the data items differ across the registries 
covered by the ICTRP, which makes the 
automated aggregate analysis of data 
impossible. To remedy this limitation, 
the staff of the ICTRP are working with 
individual registries to harmonize the 
data recording formats across all of the 
registries that are covered by the plat-
form. An alternative solution would be 
the development of algorithms to trans-
late the variable information from indi-
vidual registries into a common format 
and then classify the information into 
meaningful categories. ClinicalTrials.
gov, one of the registries that provide 
data to the ICTRP, has already shown 
that the development of such data 
classification algorithms is feasible.29,53 
Developing similar aggregation algo-
rithms for the ICTRP – and making 
both the aggregated data and the results 
of the analysis of those data publicly 
available – would be an important step 
forward not only for the ICTRP but 
also for clinical trial transparency on a 
global scale.29
In conclusion, this study shows 
that WHO’s ICTRP constitutes a valu-
able resource for assessing the global 
distribution of clinical trials and for 
informing policy development and 
priority setting for health R&D. The 
findings of this study demonstrate that 
there is little correlation between burden 
of disease and the global distribution of 
clinical trial research and that popula-
tions in lower-income countries receive 
much less attention, in terms of clini-
cal trial research, than populations in 
high-income countries. A more detailed 
understanding of the global health R&D 
“landscape” is needed to inform future 
R&D priorities. The ICTRP is one of 
several resources of information that 
will need to be “triangulated” to acquire 
a complete picture of what health R&D is 
being conducted, where and how it is be-
ing conducted, and who is conducting it. 
The ICTRP would constitute an essential 
part of any global observatory on health 
R&D.39 To increase the usefulness of the 
ICTRP further, it is important that the 
enforcement of clinical trial registration 
be increased, that the quality of the data 
in registered records be improved and 
that more possibilities for automated 
aggregate data analysis on the ICTRP 
be created. ■
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Fig. 5. Estimated numbers of trials in the International Clinical Trials Registry Platform 
recruiting participants in each of WHO’s regions, 2012
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DALY, disability-adjusted life year; WHO, World Health Organization.
Note: Only interventional and actively recruiting trials were included in the analysis. For illustration, the 
burdens of disease in countries in the same regions are also presented. The error bars on the estimates of 
trial numbers indicate 95% confidence intervals.
Table 4. Types of primary sponsor for a 5% sample of trials from the International 
Clinical Trials Registry Platform, 2012
Area of recruitmenta No. (%) of trials with  
non-industrial sponsor
No. (%) of trials with  
industrial sponsor
High-income country 1550 (88.0) 467 (94.3)
Upper-middle-income country 183 (10.4) 93 (18.8)
Lower-middle-income country 49 (2.8) 51 (10.3)
Low-income country 14 (0.8) 0 (0.0)
All 1758 (100) 495 (100)
a  Categorized according to the World Bank income groupings.21 When summed, the percentages shown 
for income groups or regions exceed 100% because some trials were recruiting in multiple countries 
belonging to more than one income group.
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摘要
使用注册临床试验的数据确定卫生研究和开发的缺口
目的  根 据 世 界 卫 生 组 织 的 国 际 临 床 试 验 注 册 平 台
（ICTRP）的数据，探索卫生研发（R&D）“全球景观”
的当前组成能够带来哪些讯息。
方法 在ICTRP数据库以介入式和主动招募方式注册的临床
试验记录中随机抽取5%的样本。
结果 总计调查了2381 个试验记录。对这些记录的分析
表明：对于因传染性、母体遗传、围产期和营养条件、
因非传染性疾病或者因受伤造成的每百万残疾调整生命
年（DALY），ICTRP数据库估计分别包含有7.4、52.4 
和6.0 项正在其中调查这些疾病负担原因的试验。在高收
入、中高收入、中低收入和低收入国家中，每百万DALY
中分别估计招募有292.7、13.4、3.0 和0.8 项注册试验。
结论 ICTRP是评估全球临床试验分布以及制订翔实卫生研
发政策的宝贵资源。就临床试验研究而言，较之高收入国
家人口，低收入国家人口得到的关注要少得多。
Résumé
Utilisation des données provenant d’essais cliniques enregistrés en vue d’identifier les disparités en matière de recherche et de 
développement dans le domaine de la santé
Objectif Étudier et, dans la mesure du possible, connaître la 
composition actuelle du «paysage mondial» en termes de recherche 
et de développement (R&D) dans le domaine de la santé à partir de 
données provenant du système d’enregistrement international des essais 
cliniques de l’Organisation mondiale de la Santé (ICTRP).
Méthodes Un échantillon aléatoire de 5% des enregistrements des 
essais cliniques qui ont été référencés comme étant interventionnels et 
recrutant activement des patients a été obtenu de la base de données 
de l’ICTRP.
Résultats Dans l’ensemble, 2381 enregistrements d’essais ont été 
étudiés. Leur analyse a montré que pour chaque million d’années de 
vie corrigées du facteur incapacité (AVCI) causées par des pathologies 
transmissibles, maternelles, périnatales et des déficiences nutritionnelles, 
par des maladies non transmissibles ou par des blessures, la base de 
données de l’ICTRP contenait respectivement environ 7,4, 52,4 et 
6,0 essais dont les causes contributives à la charge de morbidité étaient 
en cours d’étude. Pour chaque million d’AVCI dans les pays à revenu élevé, 
à revenu intermédiaire de la tranche supérieure, à revenu intermédiaire 
de la tranche inférieure et à faible revenu, il a été estimé qu’environ 
292,7, 13,4, 3,0 et 0,8 essais enregistrés, respectivement, recrutaient des 
patients dans ces pays.
Conclusion L’ICTRP constitue une ressource précieuse afin d’évaluer 
la distribution mondiale des essais cliniques, et une excellente source 
d’informations sur l’évolution des politiques de recherche et de 
développement dans le domaine médical. Les populations des pays à 
revenu faible bénéficient d’une attention bien moindre en matière de 
recherche axée sur les essais cliniques que les populations des pays à 
revenu élevé.
Резюме
Использование данных зарегистрированных клинических испытаний для определения 
различий между странами в уровне проведения научных исследований и разработок в области 
здравоохранения
Цель Изучить доступную информацию о текущем глобальном 
распределении научных исследований и разработок в области 
здравоохранения на основе данных Международной платформы 
для регистрации клинических испытаний (МПРКИ) Всемирной 
организации здравоохранения.
Методы Проведена случайная пятипроцентная выборка 
протоколов клинических испытаний из базы данных МПРКИ, 
зарегистрированных как интервенционные и с активным 
набором участников.
Результаты Всего было изучено 2381 протоколов испытаний. 
Анализ данных протоколов показал, что на каждый миллион 
лет жизни, скорректированных на инвалидность (индекс DALYs), 
обусловленных а) инфекционными заболеваниями, состоянием 
материнского и перинатального здоровья и условиями питания; 
б) неинфекционными заболеваниями и в) травмами, в базе данных 
содержится приблизительно 7,4, 52,4 и 6,0 испытаний, в которых 
исследовались причины бремени болезней, соответствующие 
указанным группам. В то же время, на каждый миллион лет жизни, 
скорректированных на инвалидность, приблизительное число 
зарегистрированных в базе данных исследований, в которых 
 نع  ةجمانلا  زجعلا  ددم  باستحاب  ةححصلما  رمعلا  تاونس  نم
 ةترفلا  تلالاتعاو  ةموملأا  تلالاتعاو  ةيراسلا  تلالاتعلاا
 يرغ  ضارملأا  نع  وأ  ةيوذغتلا  تلالاتعلااو  ةدلاولاب  ةطيحلما
 جمانبرلا  تانايب  ةدعاق  توتحا  دقف  ،تاباصلإا  نع  وأ  ةيراسلا
 7.4  لىع  تاريدقتلا  قفو  ةيريسرلا  براجتلا  ليجستل  ليودلا
 لىع ،اهيف هذه ضرلما ءبع بابسأ يرتح مت ةبرتج 6.0و 52.4و
 ةححصلما  رمعلا  تاونس  نم  ةنس  نويلم  لكل  ةبسنلابو  .لياوتلا
 ايلعلا  ةيحشرلاو لخدلا ةعفترلما  نادلبلا  في زجعلا  ددم باستحاب
 ةطسوتلما نادلبلا نم ايندلا ةيحشرلاو لخدلا ةطسوتلما نادلبلا نم
 13.4و 292.7  فيظوت مت ،لخدلا  ةضفخنلما  نادلبلاو لخدلا
.لياوتلا لىع نادلبلا هذه في ةلجسم ةبرتج 0.8و 3.0و
 ةيريسرلا  براجتلا  ليجستل  ليودلا  جمانبرلا  لكشي  جاتنتسلاا
 ةيلمع ديوزتو ةيريسرلا براجتلل يلماعلا عيزوتلا مييقتل ًمايق ًادروم
 لامج  في  ريوطتلاو  ثحبلا  لجأ  نم  تامولعلماب  تاسايسلا  عضو
 نم لقأ ردقب لخدلا ةضفخنلما نادلبلا في ناكسلا ىظيحو .ةحصلا
 في ناكسلا نع ،ةيريسرلا براجتلا في ثحبلا ثيح نم ،مماتهلاا
.لخدلا ةعفترلما نادلبلا
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производился набор участников, в странах с высоким уровнем 
доходов, выше среднего, ниже среднего и с низким уровнем 
доходов составило 292,7, 13,4, 3,0 и 0,8 соответственно.
Вывод Платформа МПРКИ представляет собой ценный ресурс 
для оценки глобального распределения клинических испытаний 
и информирования о выработке стратегии для научно-
исследовательских и опытно-конструкторских разработок в 
области здравоохранения. Населению в странах более низкими 
уровнями доходов уделяется намного меньше внимания при 
проведении клинических исследований, чем населению в 
странах с высоким уровнем доходов.
Resumen
El empleo de datos de ensayos clínicos registrados para identificar lagunas en la investigación y desarrollo sanitarios
Objetivo Analizar qué se puede aprender acerca de la composición 
actual del «paisaje global» de la investigación y desarrollo sanitarios 
(I+D) a partir de datos de la plataforma de registros internacionales 
de ensayos clínicos (ICTRP, por sus siglas en inglés) de la Organización 
Mundial de la Salud.
Métodos Por medio de un alistamiento activo se tomó una muestra 
aleatoria del 5% de los expedientes de los ensayos clínicos registrados 
como intervencionistas de la base de datos de la ICTRP.
Resultados En total, se investigaron 2381 expedientes. El análisis 
de dichos expedientes indicó que, por cada millón de años de 
vida potencialmente perdidos (AVPP) causados por enfermedades 
transmisibles, maternas, perinatales y nutricionales, por enfermedades 
no transmisibles o por lesiones, la base de datos de la ICTRP contenía 
aproximadamente 7,4, 52,4 y 6,0 ensayos, respectivamente, en los que 
se investigaban las causas de esas cargas de morbilidad. Por cada millón 
de AVPP en países con ingresos altos, medios-altos, medios-bajos y bajos, 
se alistaron aproximadamente 292,7, 13,4, 3,0 y 0,8 ensayos registrados 
en dichos países.
Conclusión La ICTRP constituye un recurso valioso para evaluar la 
distribución global de los ensayos clínicos y para informar sobre el 
desarrollo de políticas para el I+D sanitarios. Las poblaciones en países 
con ingresos bajos reciben mucha menos atención, en términos de 
investigación de ensayos clínicos, que las poblaciones en países con 
ingresos más altos.
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Table 2. The health problems being investigated in the actively recruiting, interventional trials registered on the International Clinical 
Trials Registry Platform (ICTRP), 2012
Health condition or problem No. of trials in 
samplea
Estimate and (95% CI)
Percentage of trials 
in ICTRPb
No. of trials in ICTRP
Total Per 1 000 000 DALYs
Communicable, maternal, perinatal and 
nutritional
222 10.1 (8.9–11.4) 4440 (3916–5025) 7.4 (6.5–8.3)
Infectious and parasitic diseases 132 6.0 (5.1–7.1) 2640 (2236–3111) 8.7 (7.4–10.3)
    Tuberculosis 11 0.5 (0.3–0.9) 220 (123–393) 6.4 (3.6–11.5)
    HIV/AIDS 32 1.5 (1.0–2.1) 640 (454–900) 10.9 (7.8–15.4)
    Diarrhoeal diseases 10 0.5 (0.2–0.8) 200 (109–367) 2.7 (1.5–5.0)
    Childhood cluster diseases 6 0.3 (0.1–0.6) 120 (55–261) 4.0 (1.8–8.6)
        Poliomyelitisc 1 0.0 (0.0–0.3) 20 (4–113)  –
        Diphtheria 1 0.0 (0.0–0.3) 20 (4–113) 115.2 (20.3–651.6)
        Measles 2 0.1 (0.0–0.3) 40 (11–146) 2.7 (0.7–9.8)
        Tetanus 2 0.1 (0.0–0.3) 40 (11–146) 7.6 (2.1–27.6)
    Meningitis 3 0.1 (0.0–0.4) 60 (20–176) 5.3 (1.8–15.4)
    Hepatitis B 8 0.4 (0.2–0.7) 160 (81–315) 77.4 (39.2–152.4)
    Hepatitis C 16 0.7 (0.4–1.2) 320 (197–518) 335.2 (206.6–543.0)
    Malaria 9 0.4 (0.2–0.8) 180 (95–341) 5.3 (2.8–10.0)
    Leprosy 2 0.1 (0.0–0.3) 40 (11–146) 206.4 (56.6–751.2)
    Dengue 2 0.1 (0.0–0.3) 40 (11–146) 59.7 (16.4–217.4)
    Intestinal nematode infections 1 0.0 (0.0–0.3) 20 (4–113) 5.0 (0.9–28.2)
        Ascariasis 1 0.0 (0.0–0.3) 20 (4–113) 10.8 (1.9–61.1)
    Other infectious diseasec 32 1.5 (1.0–2.1) 640 (454–900)  –
Respiratory infections 26 1.2 (0.8–1.7) 520 (355–759) 5.3 (3.6–7.8)
    Lower respiratory infections 16 0.7 (0.4–1.2) 320 (197–518) 3.4 (2.1–5.5)
    Upper respiratory infections 9 0.4 (0.2–0.8) 180 (95–341) 100.7 (53.0–191.0)
    Otitis media 1 0.0 (0.0–0.3) 20 (4–113) 13.4 (2.4–76.0)
Maternal conditions 36 1.6 (1.2–2.3) 720 (521–993) 18.5 (13.4–25.5)
    Maternal haemorrhage 1 0.0 (0.0–0.3) 20 (4–113) 4.5 (0.8–25.5)
    Hypertensive disorders of pregnancy 5 0.2 (0.1–0.5) 100 (43–234) 53.0 (22.6–123.7)
    Obstructed labour 6 0.3 (0.1–0.6) 120 (55–261) 41.6 (19.1–90.6)
    Abortion 5 0.2 (0.1–0.5) 100 (43–234) 13.5 (5.8–31.5)
    Otherc 19 0.9 (0.6–1.3) 380 (244–592)  –
Conditions arising during perinatal period 20 0.9 (0.6–1.4) 400 (259–616) 3.2 (2.1–4.9)
    Low birth weight 13 0.6 (0.3–1.0) 260 (152–444) 5.9 (3.4–10.0)
    Birth asphyxia and birth trauma 2 0.1 (0.0–0.3) 40 (11–146) 1.0 (0.3–3.5)
    Neonatal infections and other conditionsc 5 0.2 (0.1–0.5) 100 (43–234)  –
Nutritional deficiencies 8 0.4 (0.2–0.7) 160 (81–315) 4.1 (2.1–8.1)
    Protein-energy malnutrition 1 0.0 (0.0–0.3) 20 (4–113) 1.1 (0.2–6.5)
    Iron-deficiency anaemia 4 0.2 (0.1–0.5) 80 (31–205) 5.0 (1.9–12.7)
    Otherc 3 0.1 (0.0–0.4) 60 (20–176)  –
 
Non-communicable 1917 87.3 (85.9–88.7) 38 340 (37 700–38 922) 52.4 (51.5–53.2)
Malignant neoplasms 667 30.4 (28.5–32.3) 13 340 (12 511–14 199) 171.4 (160.8–182.5)
    Mouth and oropharynx cancers 19 0.9 (0.6–1.4) 385 (248–598) 101.7 (65.4–157.9)
    Oesophagus cancer 11 0.5 (0.3–0.9) 214 (119–385) 44.9 (24.9–80.8)
    Stomach cancer 34 1.6 (1.1–2.2) 685 (492–953) 91.5 (65.7–127.2)
    Colon and rectum cancers 44 2.0 (1.5–2.7) 878 (655–1174) 149.5 (111.6–199.9)
    Liver cancer 33 1.5 (1.1–2.1) 664 (474–928) 98.9 (70.6–138.3)
    Pancreatic cancer 25 1.1 (0.8–1.7) 492 (333–727) 221.9 (150.1–327.5)
    Trachea, bronchus and lung cancers 80 3.7 (3.0–4.5) 1606 (1295–1988) 136.5 (110.1–168.9)
    Melanoma and other skin cancers 12 0.5 (0.3–0.9) 236 (134–413) 333.5 (190.0–584.5)
    Breast cancer 94 4.3 (3.5–5.2) 1884 (1546–2293) 284.3 (233.2–345.9)
(continues. . .)
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Health condition or problem No. of trials in 
samplea
Estimate and (95% CI)
Percentage of trials 
in ICTRPb
No. of trials in ICTRP
Total Per 1 000 000 DALYs
    Cervix uteri cancer 14 0.6 (0.4–1.1) 278 (166–467) 74.8 (44.6–125.5)
    Corpus uteri cancer 6 0.3 (0.1–0.6) 128 (60–273) 172.5 (81.1–366.3)
    Ovary cancer 16 0.7 (0.5–1.2) 321 (198–520) 184.1 (113.5–297.9)
    Prostate cancer 35 1.6 (1.2–2.2) 707 (510–978) 383.4 (276.7–530.5)
    Bladder cancer 11 0.5 (0.3–0.9) 214 (119–385) 147.6 (81.8–265.6)
    Lymphomas and multiple myeloma 73 3.3 (2.6–4.2) 1456 (1161–1822) 339.8 (271.1–425.3)
    Leukaemia 77 3.5 (2.8–4.4) 1542 (1238–1917) 311.9 (250.4–387.8)
    Otherc 82 3.8 (3.0–4.6) 1649 (1334–2035)  –
Other neoplasmsc 25 1.1 (0.8–1.7) 500 (339–736)  –
Diabetes mellitus 85 3.9 (3.1–4.8) 1700 (1380–2091) 86.3 (70.0–106.1)
Endocrine disordersc 122 5.6 (4.7–6.6) 2440 (2052–2896) –
Neuropsychiatric conditions 282 12.8 (11.5–14.3) 5640 (5054–6283) 28.3 (25.4–31.5)
    Unipolar depressive disorders 28 1.3 (0.9–1.8) 560 (388–807) 8.6 (5.9–12.3)
    Bipolar affective disorder 8 0.4 (0.2–0.7) 160 (81–315) 11.1 (5.6–21.8)
    Schizophrenia 26 1.2 (0.8–1.7) 520 (355–759) 31.0 (21.2–45.3)
    Epilepsy 11 0.5 (0.3–0.9) 220 (123–393) 28.0 (15.7–50.0)
    Alcohol use disorders 9 0.4 (0.2–0.8) 180 (95–341) 7.6 (4.0–14.4)
    Alzheimer and other dementias 18 0.8 (0.5–1.3) 360 (228–567) 32.3 (20.4–50.9)
    Parkinson disease 11 0.5 (0.3–0.9) 220 (123–393) 128.6 (71.9–229.8)
    Multiple sclerosis 18 0.8 (0.5–1.3) 360 (228–567) 235.7 (149.3–371.6)
    Drug use disorders 16 0.7 (0.4–1.2) 320 (197–518) 38.2 (23.6–61.9)
    Post-traumatic stress disorder 9 0.4 (0.2–0.8) 180 (95–341) 51.9 (27.3–98.4)
    Obsessive–compulsive disorder 5 0.2 (0.1–0.5) 100 (43–234) 19.6 (8.4–45.8)
    Panic disorder 1 0.0 (0.0–0.3) 20 (4–113) 2.9 (0.5–16.2)
    Insomnia (primary) 5 0.2 (0.1–0.5) 100 (43–234) 27.6 (11.8–64.5)
    Migraine 6 0.3 (0.1–0.6) 120 (55–261) 15.5 (7.1–33.6)
    Otherc 111 5.1 (4.2–6.1) 2220 (1851–2658) – 
Sense organ diseases 73 3.3 (2.7–4.2) 1460 (1165–1827) 16.8 (13.4–21.0)
    Glaucoma 12 0.5 (0.3–1.0) 240 (137–418) 50.8 (29.1–88.5)
    Cataracts 6 0.3 (0.1–0.6) 120 (55–261) 6.8 (3.1–14.7)
    Refractive errors 4 0.2 (0.1–0.5) 80 (31–205) 2.9 (1.1–7.4)
    Hearing loss (adult onset) 1 0.0 (0.0–0.3) 20 (4–113) 0.7 (0.1–4.1)
    Macular degeneration and other 50 2.3 (1.7–3.0) 1000 (760–1313) 107.6 (81.8–141.2)
Cardiovascular diseases 219 10.0 (8.8–11.3) 4380 (3860–4961) 28.9 (25.5–32.8)
    Rheumatic heart disease 5 0.2 (0.1–0.5) 100 (43–234) 19.3 (8.2–45.0)
    Hypertensive heart disease 28 1.3 (0.9–1.8) 560 (388–807) 69.8 (48.4–100.6)
    Ischaemic heart disease 70 3.2 (2.5–4.0) 1400 (1111–1760) 22.4 (17.8–28.1)
    Cerebrovascular disease 40 1.8 (1.3–2.5) 800 (589–1085) 17.2 (12.6–23.3)
    Inflammatory heart disease 2 0.1 (0.0–0.3) 40 (11–146) 6.4 (1.8–23.3)
    Otherc 74 3.4 (2.7–4.2) 1480 (1183–1849) – 
Respiratory diseases 75 3.4 (2.7–4.3) 1500 (1200–1871) 25.4 (20.3–31.7)
    Chronic obstructive pulmonary disease 24 1.1 (0.7–1.6) 480 (323–712) 15.9 (10.7–23.6)
    Asthma 26 1.2 (0.8–1.7) 520 (355–759) 31.9 (21.8–46.5)
    Otherc 25 1.1 (0.8–1.7) 500 (339–736) – 
Digestive diseases 77 3.5 (2.8–4.4) 1540 (1236–1915) 36.2 (29.1–45.1)
    Peptic ulcer disease 4 0.2 (0.1–0.5) 80 (31–205) 16.1 (6.3–41.4)
    Cirrhosis of the liver 10 0.5 (0.2–0.8) 200 (109–367) 14.7 (8.0–26.9)
    Appendicitis 1 0.0 (0.0–0.3) 20 (4–113) 47.8 (8.4–270.4)
    Otherc 62 2.8 (2.2–3.6) 1240 (970–1582) – 
Genitourinary diseases 84 3.8 (3.1–4.7) 1680 (1362–2069) 113.9 (92.3–140.2)
    Nephritis and nephrosis 30 1.4 (1.0–1.9) 600 (421–854) 66.2 (46.5–94.2)
    Benign prostatic hypertrophy 3 0.1 (0.0–0.4) 60 (20–176) 22.5 (7.7–66.1)
    Otherc 51 2.3 (1.8–3.0) 1020 (778–1335)  –
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Health condition or problem No. of trials in 
samplea
Estimate and (95% CI)
Percentage of trials 
in ICTRPb
No. of trials in ICTRP
Total Per 1 000 000 DALYs
Skin diseasesc 49 2.2 (1.7–2.9) 980 (743–1290)  –
Musculoskeletal disorders 124 5.6 (4.8–6.7) 2480 (2089–2939) 80.3 (67.7–95.2)
    Rheumatoid arthritis 20 0.9 (0.6–1.4) 400 (259–616) 79.2 (51.3–122.0)
    Osteoarthritis 27 1.2 (0.8–1.8) 540 (372–783) 34.6 (23.9–50.2)
    Goutc 1 0.0 (0.0–0.3) 20 (4–113) –
    Low back painc 9 0.4 (0.2–0.8) 180 (95–341) –
    Otherc 67 3.1 (2.4–3.9) 1340 (1058–1694) –
Congenital anomaliesc 18 0.8 (0.5–1.3) 360 (228–567) –
    Down syndrome 2 0.1 (0.0–0.3) 40 (11–146) –
    Congenital heart anomalies 2 0.1 (0.0–0.3) 40 (11–146) –
    Other 14 0.6 (0.4–1.1) 280 (167–469) –
Oral conditionsc 17 0.8 (0.5–1.2) 340 (213–543) –
    Dental caries 2 0.1 (0.0–0.3) 40 (11–146) – 
    Periodontal disease 1 0.0 (0.0–0.3) 20 (4–113) – 
    Edentulism 3 0.1 (0.0–0.4) 60 (20–176) – 
    Other 11 0.5 (0.3–0.9) 220 (123–393)  –
 
Injuriesc 56 2.6 (2.0–3.3) 1120 (865–1448) 6.0 (4.6–7.7)
CI, confidence interval; DALY, disability-adjusted life year; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome.
a  Estimated percentages and numbers for the whole ICTRP were based on the results of the analysis of the records for a 5% sample of the trials registered on the 
platform. Health conditions or problems for which no trials were found in the sample were excluded from this table.
b  The percentages shown are those of the 2195 trials in the sample for which the health condition or problem studied could be classified. The condition or problem 
investigated in the other 186 trials included in the sample could not be classified because there was insufficient information in the registered records of the trial or 
because the trials included participants with many different diseases.
c  Burden-of-disease data for this condition or problem were either not available or excluded from this table for the reasons given in the methods section.
